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ABSTRACT
The majority of patients with solid malignancies die from metastatic burden. 
However, our current understanding of the mechanisms and resulting patterns of 
dissemination is limited. Here, we analyzed patterns of metastatic progression across 
16 major cancer types in a cohort of 1008 patients with metastatic cancer autopsied 
between 2000 and 2013 to assess cancer specific progression patterns of disease and 
related risk predictions. The frequency and location of metastases were evaluated in 
and across 1) 16 major cancers, 2) smoking- and non-smoking-related cancers and 3) 
adeno- and squamous cell carcinoma. Associations between primary and secondary 
sites were analyzed by the fractional and the relative risk methods. We detected 
significantly different cancer specific patterns of metastatic progression with specific 
relative risk profiles for secondary site involvement. Histology and smoking etiology 
influenced these patterns. Backward analysis showed that metastatic patterns 
help to predict unknown primary sites. Solid malignancies maintain a unique and 
recurrent organ tropism to specific secondary sites which does not appear to be 
strongly influenced by advances in cancer medicine as shown by comparison with 
previous data sets. The delineated landscape of metastatic progression patterns is a 
comprehensive data resource to both clinical and basic scientists which aids fostering 
new hypotheses for cancer research and cancer therapies. 
INTRODUCTION
In solid malignancies, not the primary tumor but 
metastatic spread and systemic disease account for 
approximately 90% of cancer-related deaths [1]. Both, 
the clinical and pathological staging system of tumors 
strongly rely on this observation and specify nodal and 
distant spread of the primary tumor with increasingly 
dismal prognosis thus serving as a rationale to stratify 
patients into different treatment arms according to their 
stage of disease [2]. Over the years, great advances in our 
understanding of malignant transformation from healthy 
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tissue via initiation, promotion, and progression towards 
the primary tumor were made [3]; however, the precise 
biological mechanisms by which individual malignant 
tumors actually metastasize to specific secondary sites still 
remain largely unexplored [4]. Our current conceptualized 
knowledge of systemic tumor expansion highlights two 
main routes through which metastases may occur and 
influence metastatic patterns, i.e., i) the microenvironment 
of the ‘host’ organ and ii) the vasculature structure and 
blood flow [5-8]. Among others [9-11], additional key 
players contributing to tumor spread are the exceedingly 
complex and highly dynamic spatial and temporal 
evolution of tumor clones during disease progression and 
therapy [12] and circulating metastasis-initiating cells 
potentially derived thereof [13, 14]. 
So far, several variably powered clinical and 
pathological studies have reported on the specific 
distribution and frequency of metastases of various 
malignancies [15-25]. These studies have substantially 
improved our comprehension of the biology and clinical 
behavior of individual tumors and not only aid in daily 
clinical reasoning and decision making but also foster 
the generation of scientific hypotheses and pave the way 
for new fields of research [26]. Until now, autopsy is the 
gold standard to definitively determine total metastatic 
disease burden and the current TNM classification even 
restricts assignment of certain pM stages to post-mortem 
examinations [2]. Notably, while most work has focused 
on single tumor entities to our knowledge there are only 
two studies which have investigated metastatic patterns 
across malignancies from different anatomical sites in 
large autopsy series reflecting the broad spectrum of 
tumors encountered in a clinical setting. Of these, the 
landmark study on carcinomas by Abrams et al. [27] dates 
back more than 60 years and a more recently published 
well-powered study by diSibio and French [28] employing 
a similar approach is built upon a dataset from 1914 to 
1943. Both studies do not reflect current cancer medicine 
since treatment strategies potentially influencing tumor 
development and progression have considerably evolved 
over the last century. Two other studies of which one 
was restricted to adenocarcinoma [29] and the other one 
aimed at predicting patterns of metastases across cancers 
linked to disease progression [30] retrieved clinical but no 
definitive autopsy data from the beginning of the 1990s for 
their respective analyses. 
Hence, we set out to comprehensively analyze the 
spatial distribution and frequency of metastases in i) 16 
major types of solid tumors ii) two more coarse-grained 
but clinically highly relevant tumor classes, i.e., smoking- 
vs. non-smoking-related cancers and adenocarcinomas vs. 
squamous cell carcinomas in a recent (2000-2013) cohort 
of 1008 metastatic cancer patients autopsied at the Charité 
University Hospital. The objectives of the study are a) to 
identify common metastatic progression patterns within 
and across different solid tumor types and b) to identify 
metastatic patterns which help to infer the primary site of 
the tumor in clinical routine diagnostics. 
RESULTS
Cohort characteristics and overview of the study 
design 
Between 2000 and 2013, a total number of 6597 
patients were autopsied at the Charité Institute of 
Pathology. For further statistical analysis, cases without 
cancer (n=4497) as well as cancer cases without metastases 
(n=1016) were excluded. Due to low prevalence, single 
cases of rare tumors or metastatic cases with more 
than one primary were not incorporated leaving a total 
cohort of 1008 autopsied patients with metastatic solid 
malignancies (Figure 1). 57% of the patients were male, 
43% of the patients were female, median age at autopsy 
was 64. For statistical analysis, tumors were classified into 
1) 16 major cancer types, 2) adenocarcinoma vs. squamous 
cell carcinoma and 3) smoking- vs. non-smoking-related 
tumors as described previously [31]. Additionally, 20 
different metastatic sites were recorded as stated in the 
Patients and Methods section. 
Frequency of metastases across 16 major cancer 
types and to 20 secondary sites
First, we evaluated whether the 16 major tumor 
entities were associated with different frequencies of 
metastases across the anatomical sites recorded. As 
displayed in Figure 2A, we detected a gradual increase 
of the number of metastases with melanoma and breast 
cancer (mean 5.9 and 5.2, respectively) as tumors with 
a high frequency of metastases at the one end of the 
spectrum and liver cancer with a comparably low number 
of metastasis (mean 2.3) at the other end of the spectrum. 
Differences in the frequency of metastases across 
primaries were highly significant (p=6.0E-14). Second, 
we calculated the number of affected patients separately 
for each secondary site (Figure 2B). We observed strong 
differences in the number of metastatic hits to secondary 
sites (p=2.5E-62), where liver, non-regional lymph nodes, 
lung, bones and pleura were affected frequently (59%, 
53%, 44%, 38% and 38%) while pancreas, skin, ovary, 
thyroid, bone marrow and spleen showed low numbers of 
metastases (all frequencies <5%).
Distribution and patterns of metastatic spread 
across 16 major cancer types
Next, we analyzed metastatic patterns for all major 
cancer types and used heatmaps for intuitive visualization 
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Figure 1: CONSORT statement (flow diagram). Out of 6597 patients autopsied in the years 2000-2013 at Charité hospital, 1008 
patients were included in the study. Inclusion criterion was a diagnosed metastatic cancer disease with primary location at one of the 16 
most common primary sites. Cancer diseases originating from more than one primary site were excluded from the study.
Figure 2: Frequency of metastases across 16 major cancer types. A) Number of metastasis sites (mean and sd) for each of the 
primary sites. The mean number of metastasis sites increased from 2.3 (liver cancer) via 4.0 (lung cancer) to 5.9 (melanoma). Different 
primary tumors had a significantly different number of metastasis sites (p=6.0E-14). B) Percentage of primary tumors that metastasized to 
20 secondary sites. The frequency of metastatic hits strongly depends on the localization of the secondary site (p=2.5E-62). 
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of metastatic clusters. Figure 3A demonstrates how often 
a given primary cancer in our cohort spreads to one of 
the 20 different anatomical sites. For example, while 
breast cancers tended to metastasize to liver, bones, non-
regional lymph nodes, lung and pleura (80%, 79%, 60%, 
54% and 52%), prostate cancers were predominantly 
associated with metastatic spread to the bone (91%) and 
much lower frequencies (<50%) of metastases in other 
anatomical sites. Figure 2B illustrates a reverse scenario, 
which infers the quantitative contribution of cancer types 
to the metastatic burden of a secondary site. For example, 
lung and breast cancer accounted for the majority (24% 
and 7%) of brain metastases while splenic metastasis 
frequently occurred from lung cancers and melanomas 
(32% and 26%). As depicted in Figure 2C, we also found 
patterns of co-occurrence among metastases across 
cancers. For example, pulmonary metastases were often 
associated with metastatic spread to distal lymph nodes, 
liver, pleura and the bones (61%, 60%, 49% and 47%). 
Relative risk analysis of metastasis across 16 
major cancer types
Complementing our results on metastatic patterns 
and to narrow in on the clinical situation, we additionally 
calculated the relative risk (RR) for each major cancer to 
metastasize to one of the 20 recorded distant anatomical 
sites as shown in Figure 4A. Calculation of RRs and 
significance assessment allowed to identify associations 
that are enriched or depleted compared to the entire cohort 
of 1008 primary tumors. Melanoma showed strongly 
enhanced metastatic progression to spleen (RR=8.9), 
skin (RR=5.6) and meninges (RR=4.0). Breast cancer 
showed strongly enhanced metastatic progression to the 
ovaries (RR=4.8). Moreover, in Figure 4B, we plotted the 
relative risk with which two metastases from different 
anatomical sites co-occur. The strongest enrichment of 
co-associations between two metastatic sites was detected 
between pancreas and skin, pancreas and ovaries as well 
as pancreas and spleen (all RRs >5).
Patterns of metastatic progression
Figure 5 summarizes the data from our pattern and 
risk analysis as clock plots for every major cancer entity. 
For example, while the RR of breast cancer to metastasize 
to the liver, bone and pleura was enhanced (RR=1.4, 
2.0 and 1.4), the RR of bone metastases in pancreatic 
cancer was diminished (RR=0.37), but enhanced for 
liver metastases and peritoneal spread (RR=1.4 and 1.7). 
In contrast, melanomas showed an increased RR for 
spreading to specific anatomical sites (including spleen, 
meninges, brain and heart) which are usually not at high 
risk when compared to metastatic patterns of other major 
cancers.
Influence of smoking and histology on metastatic 
patterns 
We also tested whether spread to secondary sites 
is influenced by exposure to tobacco smoke and the 
phenotype of tumor cells. To this end, we classified all 
cancers investigated here in smoking- and non-smoking-
related cancers and separately stratified cancers in either 
squamous cell carcinoma or adenocarcinoma where 
applicable (for details see Patients and Methods section 
as well as Figure 1). As depicted in Figure 6, we found 
significant differences in the metastatic patterns of 
squamous cell carcinoma and adenocarcinoma, smoking- 
and non-smoking-related cancers as well as for node- 
positive and node-negative cancer. When applying the 
histological classification to all primary sites, we detected 
significantly increased numbers of metastases to the 
peritoneum in adenocarcinoma compared to squamous 
cell carcinoma (36% vs. 11%, p=2.2E-18). In a subgroup 
analysis of lung cancer, we found adenocarcinoma 
compared to squamous cell carcinoma metastasizing 
significantly more often to the brain (46% vs. 20%, 
p=0.0021) and to the adrenal gland (49% vs. 24%, 
p=0.0045). In smoking-related cancer compared to non-
smoking-related cancer, we found significantly increased 
numbers of metastases to the adrenal gland (26% vs. 13%, 
p=7.4E-07), to the kidney (17% vs. 10%, p=0.00047) and 
to the brain (23% vs. 16%, p=0.0065). Furthermore, we 
found node-positive (N+) cancers to have a drastically 
increased probability to spread to distant lymph nodes 
compared to node-negative (N-) metastatic cancer 
(63% vs. 19%, p=4.2E-25). The association between 
metastases in local lymph nodes and metastases in distal 
lymph nodes could be found in many of the cancer types 
including biliary cancer, breast cancer, colorectal cancer, 
gastric cancer, liver cancer, lung cancer, neuroendocrine 
cancer and ovarian cancer. Furthermore, the probability 
to metastasize to peritoneum (33% vs. 17%), to pleura 
(42% vs. 26%), to adrenal gland (24% vs. 13%) and to 
pericardium (10% vs. 4%) was significantly increased 
in N+ cancer compared to N- cancer. In contrast, the 
percentage of bone metastases (38% vs. 39%), brain 
metastases (20% vs. 20%) and lung metastases (43% 
vs. 39%) did not change much. Finally, sex was not 
significantly associated with distinct patterns of metastases 
(data not shown).
Prediction of primary cancers by metastatic 
patterns
Given the frequent clinical question of an unknown 
primary in the setting of widely metastatic disease, we 
investigated whether distant metastasis location may 
be used to predict the primary tumor thereby reflecting 
a clinical scenario where the primary localization has to 
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Figure 3: Metastatic progression from 16 primary sites to 20 secondary sites. A) Percentage of primary tumors progressing 
to a secondary site. B) Percentage of metastases originating from a primary site. C Co-occurrence analysis of metastases. For each pair of 
secondary sites, the percentage of primaries with metastases at both sites relative to the number of primaries with metastases minimum at 
one of the two sites is shown.
Figure 4: Relative risk (RR) analysis of 16 primary and 20 secondary sites. A) RR for progression from a primary site to a 
secondary site. B) RR for co-occurrence of two secondary sites. Significantly enhanced RRs (red boxes) and significantly reduced RRs 
(green boxes) compared to the entire cohort.
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Figure 5: Metastatic progression from 16 primary sites to 20 secondary sites. Circle size is proportional to the number of 
tumors or metastases. Orange circles refer to the number of metastases from a single primary site. Arrows width is proportional to the 
percentage of tumors that metastasize from a primary site to a secondary site. Colored arrows refer to significant enrichment (red arrows) 
or a significant depletion (green arrows) of a metastatic route. RR = relative risk.
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be infered in patients presenting with metastatic disease. 
As shown in Figure 7, metastases in the pericardium, 
kidney, brain and adrenal glands, for instance, were 
associated with a high probability to originate from lung 
cancer (OR=3.03, OR=2.73, OR=4.21 and OR=4.54), 
while the probability that skin metastases stem from lung 
cancer was low (OR=0.23). Bone metastases had a high 
probability to stem from a primary of the prostate or breast 
(OR=25.64 and OR=6.78), but had a low probability to 
occur from primaries of the gastrointestinal system or of 
the ovaries (OR=0.13, OR=0.31 and OR=0.45). As yet 
another example, breast cancer was characterized by a 
fairly high probability of metastatic spread to the bone, 
liver, ovaries, skin and meninges (OR=6.78, OR=2.94, 
OR=7.80, OR=3.80 and OR=3.05) while the chance of 
distant metastases in heart and kidney was low (OR=0.23 
and OR=0.33). Thereby, our data provide an up-to-date 
dataset to support determination of the site of origin in the 
cancer of unknown primary in a clinical setting.
Using multinomial regression, we investigated 
the degree, how much the metastasis patterns were 
predictive for the type of primary tumor. To this end, 
we used a multiple random sampling approach, where 
1000 training sets of 672 patients (2/3) were randomly 
drawn and the remaining patients (1/3) were included in 
the test sets. Using this approach, 34% (29% - 38%) of 
primary locations were predicted correctly, for 48% (44% 
- 53%) of patients the true primary location was among 
the two top predictions and for 59% (54% - 63%) of the 
patients the true primary location was among the top three 
locations. Using the approach of the top three locations, 
more than half of the primary locations could be predicted 
for lung cancer (91%), breast cancer (81%), pancreatic 
cancer (64%), prostate cancer (61%), colorectal cancer 
(59%) and esophageal and gastric cancer (56%).
Lifetime analysis 
Finally, we investigated the influence of the location 
of the primary site and the localizations of secondary 
sites on the total cancer-related lifetime of the patients. 
It should be noted that this kind of analysis is different 
from an analysis of clinical outcome, where not the total 
Figure 6: Comparison of the metastatic progression in selected tumor subgroups: A) squamous cell cancer vs. 
adenocarcinoma, B) squamous cell lung cancer vs. adenocarcinoma of the lung, C) smoking-related vs. non-smoking-related cancer, D) 
node- positive vs. node-negative cancer. Circle size is proportional to the number of tumors or metastases. Orange circles refer to the 
number of metastases from a single primary site. Arrows width is proportional to the percentage of tumors that metastasize from a primary 
site to a secondary site. Colored arrows refer to significant enrichment (red arrows) or a significant depletion (green arrows) of a metastatic 
route. RR = relative risk, * = significant different metastasis frequency between subgroups.
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lifetime, but the remaining lifetime after cancer diagnosis 
or surgery is analyzed. The lifetime analysis describes 
the burden of tumors and metastases at defined primary 
and secondary sites for a population rather than the 
prognosis for an individual patient after cancer diagnosis. 
Metastases in the ovaries (HR=3.4, p<0.001), the heart 
(HR=1.6, p=0.001), the brain (HR=1.5, p<0.001), the 
meninges (HR=1.4, p=0.022), the distal lymph nodes 
(HR=1.2, p=0.009) and the bones (HR=1.2, p=0.34) 
were associated with a significantly shortened lifetime. 
Moreover, compared to the other metastatic cancers, we 
found a significantly prolonged lifetime for metastatic 
prostate cancer (HR=0.45, p=0.001) and a significantly 
shortened lifetime for metastatic testicular cancer 
(HR=32.8, p<0.001) and metastatic esophageal/gastric 
cancer (HR=1.3, p=0.043). The former result corresponds 
to generically late occurrence and slow progress of 
prostate cancer compared to other cancer types, the later 
result reflects that testicular cancer often occurs early 
during lifetime.
DISCUSSION
While solid malignancies confined to the primary 
site are potentially amenable to therapy with curative 
intent, the majority of these tumors will either primarily 
present as extended disease with spread to distant 
anatomical sites or evolve towards systemic disease over 
time. Despite current advances, it is the metastatic spread 
where even sophisticated novel approaches of multimodal 
therapy will eventually fail. It is therefore not surprising 
that metastatic cancer accounts for more than 90% of 
cancer-related deaths [1, 6]. Impacting both clinical work 
and basic research, we still struggle with understanding 
why and how specific tumors metastasize to specific 
anatomical sites with different propensities. 
Here, we provide a comprehensive analysis of 
metastatic patterns across major cancer types that is built 
upon definitive autopsy data rather than clinical data 
potentially entailing problems with the inherently limited 
sensitivity and more importantly specificity of clinical and 
radiographic examinations. Our work provides a detailed 
up-to-date account of differences in metastatic progression 
across solid malignancies in a cohort comprising the last 
Figure 7: Models for prediction of the primary cancer sites from secondary cancer sites (metastases). For each primary 
site, multivariate logistic regression was executed to obtain odd ratios (ORs) associated with the secondary sites. Secondary sites associated 
with significantly higher probability for the primary site (red boxes) and secondary sites associated with significantly lower probability for 
the primary site (green boxes).
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14 years (2000-2013) complementing and extending 
previous approaches [26, 27] but also serving as a 
current framework to foster research efforts in both basic 
science and clinical oncology. Moreover, following up 
on the elegant study by Chen and colleagues [30] we 
aimed at defining and predicting networks of metastatic 
progression, which may help to infer the primary tumor 
localization when patients present with metastatic disease 
or so called (with dash) cancer of unknown primary (CUP) 
[37].
We observed strongly (and significantly) different 
metastasis patterns across 16 major cancer types. Very 
interestingly, two earlier autopsy studies by Abrams et 
al. [27] and diSibio and French [28] employed a similar 
approach and therefore in principle allow for a comparison 
between different eras of cancer medicine (1914-1947 
vs. 2000-2013). Comparing the number of patients, our 
study included almost the same number as Abrams et al. 
[27] did 65 years ago. Both collectives comprise cases 
from a relatively limited period of five and 13 years, 
respectively. In contrast, the much larger number of cases 
presented by diSibio [28] mirrors a significantly longer 
time period of thirty years. A brief overview of the study 
characteristics is provided in Supplementary Table 1. 
However, it is important to note however, that none of the 
three studies was designed for direct cross-comparison 
and the composition of the respective patient collectives 
including risk factors and frequencies of cancer types 
among others certainly vary to some extent. Nevertheless, 
cautious comparison may yield some insight since diSibio 
and French specifically stated in their paper [28] that the 
patients included in their study neither received chemo- 
nor radiotherapy while the patient analyzed in our cohort 
were treated in accordance with the German guidelines 
effective at the time which includes neoadjuvant as well as 
adjuvant chemo- and radiotherapy regimens. 
Interestingly, our work and the study by diSibio and 
French [28] reflecting the years 1914-1943 yielded similar 
results with breast, lung and kidney cancer developing 
high numbers of metastases and, for example, liver cancer 
with a comparably low metastases frequency. Moreover, 
DiSibio and French [28] reported the most frequently 
affected secondary sites as regional and distant nodes 
followed by liver, lung and bone; a rank order which is 
in line with our data (not accounting for regional lymph 
nodes) albeit at somewhat different frequencies (see 
Supplementary Table 1). Abrams et al. [27] provided 
detailed data on several cancer types, including breast 
and lung cancer with lung, bone, pleura and liver as the 
most frequently affected secondary sites in breast cancer 
patients and lung, liver, adrenal glands and bone as the 
most frequent metastatic sites in lung cancer patients, 
respectively. These results collected in the 1940s are 
in good accordance with our data set compiled at the 
beginning of the 21st century. In summary, these data might 
indicate that despite considerable improvements in therapy 
Figure 8: Multivariate analysis of lifetime using Cox proportional hazard modeling. Analysis of the influence of the primary 
tumor site and of secondary tumor sites on total lifetime. Different than in overall survival analysis (time of survival after the first cancer 
diagnosis) the total lifetime (patient age at death) is analyzed. Only cancer-related deaths are taken into consideration. HR = hazard ratio.
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over the last century metastatic progression patterns are 
quite robust and do not seem to be strongly influenced by 
advances in cancer medicine. 
Given the fact that, for example, melanomas have a 
higher rate of metastatic spread compared to each of the 
other major cancer our data also suggest that each tumor 
has a distinct and specific capacity and efficiency to evolve 
cell clones which are capable of spreading and seeding in a 
given period of time. These results match current findings 
demonstrating cancer-specific intratumoral heterogeneity 
[12] eventually fostering cancer-specific evolution of 
metastatic clones [10] as already conceptualized by 
Nowell in 1976 [38].
Moreover, our results clearly demonstrate that apart 
from tumor-specific metastasis rates cancers also have 
entity-specific predilection sites for tumor expansion. As 
already hypothesized by Ewing in 1919 [39], these are 
certainly -in part- attributable to the anatomical structure of 
vessels and blood flow as the underlying transport vehicle 
and prerequisite for hematogenous spread or the lymphatic 
system with the lymphatic vessels as possible entry 
and exit point for the tumor cells. Starting with clinical 
observations of contiguous development of metastases in 
axillary lymph nodes of breast cancer patients reported 
by Halsted in 1907 [40], nowadays it is well established 
that lymph node metastases are a prognostic factor for 
organ metastases in melanoma and particularly breast 
cancer [41,42]. However, the stepwise progression of 
malignant cells from tumor to sentinel lymph nodes and 
from thereon to distal lymph nodes and organs has not 
been demonstrated conclusively [43]. Our results showing 
that node-positive cancers of different entities (including 
breast, colorectal and gastric cancer among others) spread 
much more often to distant lymph nodes than node-
negative cancers (63% vs. 19%, p=4.2E-25, Figure 6D) 
suggest that cellular mechanisms facilitating access to the 
local lymphatic system and hence the lymphatic system 
are crucially required for metastatic dissemination to 
distant lymph nodes and challenge the view that spreading 
from local to distant nodes is primarily enabled by blood 
vessels. Moreover, as shown by us, several node-positive 
cancers also appear to be have a higher likelihood to 
spread to distant sites compared to node-negative cancers. 
These findings may support the notion that the lymphatic 
system in conjunction or even interaction with blood 
vessels contributes to the colonization of distant sites. 
However, anatomy and physiology of the 
hematologic and lymphatic alone hardly explain why, 
according to our study, e.g., melanomas are particularly 
prone to metastasize to the spleen or prostate cancer as 
well as breast cancers are bone-seeking malignancies 
whereas colorectal cancers are not. In this context, it is 
noteworthy that our results also demonstrate a variable 
risk of co-occurrence of two metastases at different 
anatomical sites with some pairs (e.g. ovarian and 
pancreatic metastases) at high risk and others (e.g. bone 
marrow and peritoneum) at low risk. Originally proposed 
as ‘seed and soil’ hypothesis by Paget in 1889 [44], these 
results clearly imply mechanisms beyond anatomy where 
either certain molecular features acquired during tumor 
evolution serve as one master key for distinct locks or the 
microenvironment of two host organs resemble each other 
thereby equally facilitating metastasis in two anatomically 
distinct locations. 
As illustrated and summarized in Figure 5, every 
single cancer type investigated here shows a specific 
organ tropism resulting in recurrently affected secondary 
sites, which characterizes every tumor biologically and in 
turn clinically. Matching the data from Chen et al. [30] we 
detected e.g. for colorectal cancer statistically significant 
increased relative risks to spread to liver and peritoneum, 
which according to the findings from Chen et al. [30] is 
already inherent at the time of diagnosis and obviously 
conserved during tumor evolution until death. In contrast, 
melanomas display a peculiar pattern of relations to 
various secondary sites whereas kidney cancer shows a 
strong risk for pulmonary metastases followed by spread 
to bones, pleura and peritoneum but a comparably lower 
risk to metastasize to the liver.
We also show that the progression patterns from 
primary to secondary sites is influenced by tumor tissue 
histology and etiology of smoking. As the tumor phenotype 
is an integral expression of genomic, epigenetic, proteomic 
and other biological characteristics in cancer cells, it is 
likely that phenotypic characteristics also reflect specific 
metastatic patterns. Among others [45], smoking directly 
damages the genetic integrity of cells, specifically by G·C 
to T·A transversions and hence smoking history can be 
traced by specific genetic signatures imprinted throughout 
the cancer cell genome [46]. With these considerations, 
differences in metastatic behavior between smoking- and 
non-smoking-related cancers do not appear unlikely. 
Our findings indicate that every primary tumor 
appears to harbor the capability to facilitate a specific 
pattern of distant colonization which is dynamic over the 
course of disease but highly recurrent across individual 
cancer of the same entity. Hence, it might provide new 
insights to shift the view on solid tumors away from 
the sole primary confined to a certain organ eventually 
prone to metastasize towards a disease where tumor cells 
of origin establish and maintain a network to specific 
secondary sites with ties of different strength. Of note, 
this view does not challenge the stochastic foundations 
of metastatic progression which play a crucial and well 
established role but acknowledges the notion that besides 
randomness there are obviously nonrandom determinants 
[47] that ultimately result in or -in other words- can be 
readout as recurrent and cancer type specific patterns of 
metastatic disease. This network may be maintained by 
cancer specific circulating tumor cells trafficking along 
pre-established anatomical routes (links) which acquired 
specific properties in the primary by chance that in 
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principle allow colonization of distant organs [14,48] and 
also self-seeding [49] of the primary tumor (nodes). While 
the overall success rate of metastatic spread appears to 
be rather low [47] and is influenced by randomness it is 
striking that once colonization is successful, a recurrent 
pattern of affected organs emerges across individual 
tumors of the same entity. As shown by us and others 
[27,28], there is a certain degree of overlap between 
metastatic patterns of distinct entities which may be 
influenced by anatomical conditions but may also suggest 
common traits of the respective primaries. It is also 
tempting to speculate whether organ-specific colonization 
is influenced by -possibly developmentally- imprinted 
molecular similarities shared between the organ from 
which the primary evolves and secondary sites colonized 
by the primary. Comparing our results with the data from 
diSibio and French [28], Abrams et al. [27] and Chen et al. 
[30] as well as considering reduced cancer mortality over 
the last 100 years [50], the occurrence of cancer-specific 
network-like spreading to distant sites may be delayed or 
even halted in some cases but seems not to be prevented 
or fully disrupted by current systemic therapies despite 
significant advances in the understanding of cancer and in 
cancer medicine. 
In summary, the delineated landscape of metastatic 
progression provides a comprehensive resource for clinical 
oncologists, physician-scientists and basic scientists. Our 
current comprehensive analysis of metastatic patterns 
across major cancer types in a large autopsy series 
strongly supports the assumption by Polzer and Klein [13] 
as well as other groups that our efforts in understanding 
when and how specific progression networks evolve and 
being maintained rather than exclusively focus on the 
primary tumor crucially require significant enhancement 
by inclusion of the possible pathways of metastatic 
progression to develop innovative and effective strategies 
abrogating metastatic disease in the future. 
PATIENTS AND METHODS
Study cohort and ethical approval
The retrospective study using anonymized patient 
data was approved by the local ethics committee 
(application number: EA1/077/14). All adult autopsy 
reports performed at the Charité Institute of Pathology 
(Campus Charité Mitte and Campus Virchow Hospital), 
Berlin, Germany, from the years 2000-2013 were 
reviewed retrospectively. Out of a total number of 
6597 autopsied patients, 1008 patients diagnosed with 
metastatic cancer progressed from one of 16 primary 
cancer sites were included in the study (Figure 1). 
Patients with hematological malignancies and sarcomas 
were excluded. All patients underwent a complete 
clinical autopsy, including histological assessment of 
all major internal organ systems including the brain. 
For each patient, a definitive structured autopsy report 
stating final anatomical diagnoses was established that 
included detailed gross and microscopic findings as 
well as clinicopathologic correlations including case 
discussion. Autopsies were performed according to 
established protocols and reviewed and presented by 
at least one board-certified pathologist as described 
previously [31, 32]. Briefly, each autopsy followed a 
standard operating procedure including macroscopic and 
microscopic examination, the former comprising external 
inspection, initial dissection and internal examination. 
Evisceration was usually achieved by a modified en bloc 
method of Ghon which preserves organ blocks (brain, 
cervico-thoracic, upper abdominal part, small and large 
intestine, genitourinary) and thus enables evaluation of 
the interrelationship of organs, lymphatic drainage and 
vasculature (accounting for regional disease in an organ 
system). In single cases organs were removed one by one. 
This was followed by three dimensional inspection of each 
organ and organ system. Hollow organs, ducts and vessels 
were opened to evaluate the inner linings and surfaces. 
Organs were sliced serially at approx. 1.0 cm intervals in 
parasagittal, coronal and horizontal planes as appropriate. 
For oncological cases, microscopic sampling included any 
lesion or tissue alteration (lower limit: approx. 0.3 cm in 
diameter) that appeared suspect at macroscopic evaluation. 
Generally, there were no restrictions on the extent of 
examination. Additionally, standard sampling (in the 
absence of evident macroscopic alterations) included the 
heart including coronary arteries, left and right lung, liver, 
pancreas, spleen, and bone. For each case, all collected 
tissue samples were formalin fixed and paraffin embedded 
(FFPE) with osseous tissue decalcified in EDTA prior to 
FFPE. Subsequent microscopic evaluation with bright 
field microscopes was primarily performed on HE-stained 
slides, accompanied by additional histochemical stains and 
immunohistochemistry if necessary. 
Cancer classification
For statistical analyses, we recorded age, sex, life 
span, the cause of death, tumor type, number of metastases 
and metastatic sites. The total cohort was subdivided into 
different tumor types as depicted in Figure 1. 
Three classification schemes were used for a 
specific analysis of metastatic patterns across cancers. 
First, primary tumors were stratified into 16 anatomical 
sites (lung, esophagus and stomach, colon and rectum, 
breast, pancreas, biliary system, head and neck, kidney, 
neuroendocrine tumors, prostate, liver, urinary tract, 
melanoma, ovary, cervix and testicles). Secondly, patients 
were classified in two main histological tumor types: 
adenocarcinoma (n=635) and squamous cell carcinoma 
(n=112). Third, tumors were grouped according to 
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the major risk factor smoking. To this end, the degree 
of relation to tobacco smoking was graded based on 
the population attributable fraction (PAF) as reported 
previously [32,33]. Specifically, tumor types with PAF 
≥20% were classified as smoking-related, and cancer types 
with PAF <20% were classified as non-smoking-related. 
As a result, smoking-related cancers (n=592) comprised 
lung, head and neck, esophagus and stomach, kidney, 
pancreas, urinary system and cervix cancer. Non-smoking-
related cancers (n=416) included malignancies of the 
colon, rectum, liver, ovary, breast, biliary tract, prostate, 
testicle as well as melanoma and neuroendocrine cancer. 
In addition to full UICC staging [2], we employed 
a more fine-grained classification scheme that accounts 
for the most common metastatic sites throughout the 
body. The anatomical sites of metastatic spread of each 
metastasis were recorded as follows: adrenal gland (ADR), 
bone (OSS), bone marrow (MAR), brain (BRA), heart 
(HEA), kidney (REN), liver (HEP), lung (PUL), non-
regional lymph nodes (LYM), meninges (MEN), ovary 
(OVA), pancreas (PAN), pericardium (PC), peritoneum 
(PER), pleura (PLE), skin (SKI), soft tissue (ST), spleen 
(SPL) and thyroid (THY). Metastases occurring at rarer 
sites were recorded as other site (OTH); resulting in a 
total of 20 different locations. Lesions in the bone marrow 
which were ambiguous at the macroscopic level but 
confirmed as metastasis by microscopy were classified 
as MAR while osseous metastases already apparent on 
the macroscopic level with involvement of cortical and 
cancellous bone and corroborated by histology were 
classified as OSS. 
Data analysis
The software environment R [34] was used for 
statistical computing and graphic production. Values 
of p<0.05 were considered statistically significant. The 
number of metastatic sites (mean and sd) was calculated 
for each of the primary sites and significance was assessed 
using the Kruskal-Wallis rank test.
Two kinds of analysis methods were applied to 
analyze the association between primary and secondary 
sites or between two secondary sites: The fractional 
method simply estimates the fraction of tumors that 
metastasize from a primary to a secondary site, while 
the relative risk (RR) method quantifies enrichment or 
depletion of an association compared to the situation in 
the entire cohort. For two localizations a and b (either both 
secondary sites or a primary and b secondary site) the RR 
was calculated as
wherein the expressions f(…) denote relative 
frequencies with respect to the total number of patients 
in the study. Significances of RRs were assessed using 
Fisher’s exact test.
Hierarchical clustering of percentages was 
conducted using the Manhattan distance as dissimilarity 
measure and average linkage to compare between clusters. 
For relative risk (RR) and odds ratio (OR) analysis, 
log2 data were used as input for heatmap and clustering 
analyses. Hierarchical clustering of RRs and ORs was 
conducted using the Euclidean distance as dissimilarity 
measure and average linkage to compare between clusters.
To identify significantly enriched or depleted targets 
of metastatic progression, p-values were corrected using 
the Benjamini-Hochberg method (FDR control at 5%) 
separately for Figures 5, 6A, 6B, 6C and 6D. Metastatic 
progression patterns were visualized using Cytoscape [35] 
and the R package RCytoscape [36]. Node size was chosen 
proportional to the number of tumors or metastases. Edge 
thickness was chosen proportional to the percentage of 
primary tumors that metastasize to a secondary site.
Two approaches were employed to infer the 
primary cancer location from the secondary locations: 
First, separately for each of the 16 primary locations, 
we executed multivariate logistic regression with the 20 
secondary locations as covariates. As results, we obtained 
odd ratios (ORs) describing an increased or decreased 
probability for a tumor at a primary site associated with 
a metastasis that occurred at one of the secondary sites. 
Second, as in Chen et al. [30], a model for prediction 
of the primary site was fitted using multinomial logistic 
regression. The logistic model was validated using a 
multiple random cross-validation protocol: 1000 training 
sets of 672 patients (2/3) were randomly drawn and the 
remaining patients (1/3) were included in the test sets. 
Prediction success was reported as mean value with 95% 
confidence intervals estimated from the 1000 training-test 
splits.
Analysis of cancer-related lifetime was executed 
using Cox proportional hazard modeling in SPSS (IBM 
Corporation) with sex, primary tumor sites and secondary 
metastasis sites as covariates. Hazard ratios (HRs) of the 
primary sites were calculated relative to lung cancer that 
was the most common primary site. Only cancer-related 
deaths were considered as event, cases with other causes 
of death were included in the analysis, but marked as 
censored. Significance of the covariates was assessed 
using the Wald test.
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